DAB2 in LGMD R2: a molecular link between disease progression and lipid dysregulation.

Area of Science:

• Biochemistry
• Genetics
• Cell Biology

Background:

• Limb-girdle muscular dystrophy R2 (LGMD R2) is a debilitating genetic disorder resulting from dysferlin deficiency.
• Current monitoring and therapeutic evaluation for LGMD R2 are hindered by a lack of reliable clinical biomarkers.

Purpose of the Study:

• To identify a novel molecular and clinical indicator for assessing disease state and progression in LGMD R2.
• To investigate the role of Disabled-2 (DAB2) in the pathophysiology of LGMD R2, particularly concerning lipid metabolism.

Main Methods:

• Transcriptomic profiling of patient-derived induced pluripotent stem cell (iPSC)-derived myotubes.
• Validation of DAB2 expression in muscle biopsies from LGMD R2 patients and dysferlin-deficient mice.
• Assessment of AAV-mediated dysferlin gene therapy effects on DAB2 levels.
• Investigation of DAB2's role in lipid accumulation using siRNA knockdown in LGMD R2 myotubes.

Main Results:

• Disabled-2 (DAB2) expression was significantly upregulated in LGMD R2 patient cells and tissues, correlating with disease severity.
• Restoration of dysferlin via AAV gene therapy normalized DAB2 levels, indicating its responsiveness to therapeutic intervention.
• DAB2 expression paralleled lipid deposition in affected tissues, and its knockdown reduced lipid accumulation in patient-derived myotubes.

Conclusions:

• DAB2 serves as a crucial molecular and clinical biomarker for LGMD R2, reflecting disease activity and progression.
• DAB2 is mechanistically linked to dysferlin deficiency, altered lipid handling, and disease severity in LGMD R2.
• DAB2 holds potential as a prognostic marker and a measure of therapeutic response for LGMD R2 patients.